About Jointown

About Jointown

Group Profile

More
As a technology-driven comprehensive service provider for the whole chain pharmaceutical industry, Jointown is based on the comprehensive health industry. Its main business comprises the following six parts: digital pharmaceutical distribution and supply chain business, general agency brand promotion business, pharmaceutical industrial self-production and OEM business, new retail and Ten-Thousand Store Alliance Plan business (C-end), medical health (C-end) and technology value-added services, and digital logistics technology and supply chain solutions.

In the future, Jointown will continue to promote the comprehensive service model of "pharmaceutical distribution + logistics distribution + product promotion", follow the emerging trends in the market and take actions accordingly to maintain a robust growth.
billion RMB
Operating Income in 2025
million RMB
R&D Investment in 2025
%
CAGR from 2010 to 2025
th
Top 500 Chinese Enterprises

Corporate Strategy

New Products
More
Jointown gains product leadership through diverse approaches such as R&D, acquisitions, and partnerships, increases investment in the industrial sector to build proprietary generic drug brands and actively participates in national centralized procurement; meanwhile, the Company expands the comprehensive health product portfolio beyond chemical drugs to continuously enhance corporate profitability.
New Retail
More
Under the Best Pharmacist Pharmacy brand, Jointown provides patients with efficient, precise, and convenient health experiences through a combination of online and offline channels, the Ten-Thousand Store Alliance Plan, B2B/B2C integration, O2O, self-operated flash warehouse stores, insurance, personal health management, tri-medical service centers, and other business models.
New Medical Services
More
Through the clinic model, Jointown provides LBX with cost-effective basic medical services featuring low cost, high efficiency, and digital intelligence. By adopting platformization approaches such as self-built + partnership and supply chain + franchise models, we enhance the competitiveness of our clinic business.
New Service Solutions
More
Jointown has been strengthening service awareness: manufacturer services involve providing medical insurance and centralized procurement qualification support to secure distribution rights; digital intelligence services encompass SPD, medical consortium systems, smart traditional Chinese medicine pharmacy systems, Zhiyaotong, Mendiantong, traceability, flow analysis, and more; C-end services include insurance, personal health management, single-disease management, B2C, and others; along with comprehensive health-related collaborative services.
Digital Intelligence
More
Built on a foundation of big data, AI, Internet of Things, and other technologies, Jointown empowers business competitiveness, improves management and operational efficiency, enhances digital decision-making capabilities, and builds an intelligent supply chain system, advancing from digitalization toward digital intelligence.
Capitalization
More
Through market capitalization management, REITs, spin-off IPOs, mergers and acquisitions, equity investments and other means, Jointown provides financial support for strategic expansion and innovation, optimize the balance sheet, enhance market valuation, and achieve long-term sustainable value creation.

Group Leadership

More
Board Of Directors
More
Management Team
More

Development History

undefined undefined
undefined
2021
2022
2023
2024
2025

Corporate Honors

More
No. 165 - Fortune China 500 (2025) Fortune
No. 55 - Top 500 Chinese Private Enterprises 2024 All-China Federation of Industry & Commerce
2024 Information Disclosure Rating "A" Shanghai Stock Exchange
2024 ESG Advancement Contribution Award China Association of Pharmaceutical Commerce
2024 Top 100 Listed Companies for SME Investor Protection CG50 Forum (5th Theme Forum of the 18th China Corporate Governance Forum)
Special Contribution Award of the Year 2024 Red Cross Society of China Hubei Branch

About Jointown

About Jointown

Group Profile

More
As a technology-driven comprehensive service provider for the whole chain pharmaceutical industry, Jointown is based on the comprehensive health industry. Its main business comprises the following six parts: digital pharmaceutical distribution and supply chain business, general agency brand promotion business, pharmaceutical industrial self-production and OEM business, new retail and Ten-Thousand Store Alliance Plan business (C-end), medical health (C-end) and technology value-added services, and digital logistics technology and supply chain solutions.

In the future, Jointown will continue to promote the comprehensive service model of "pharmaceutical distribution + logistics distribution + product promotion", follow the emerging trends in the market and take actions accordingly to maintain a robust growth.
billion RMB
Operating Income in 2025
million RMB
R&D Investment in 2025
%
CAGR from 2010 to 2025
th
Top 500 Chinese Enterprises

Corporate Strategy

New Products
Jointown gains product leadership through diverse approaches such as R&D, acquisitions, and partnerships, increases investment in the industrial sector to build proprietary generic drug brands and actively participates in national centralized procurement; meanwhile, the Company expands the comprehensive health product portfolio beyond chemical drugs to continuously enhance corporate profitability.
More
New Retail
Under the Best Pharmacist Pharmacy brand, Jointown provides patients with efficient, precise, and convenient health experiences through a combination of online and offline channels, the Ten-Thousand Store Alliance Plan, B2B/B2C integration, O2O, self-operated flash warehouse stores, insurance, personal health management, tri-medical service centers, and other business models.
More
New Medical Services
Through the clinic model, Jointown provides LBX with cost-effective basic medical services featuring low cost, high efficiency, and digital intelligence. By adopting platformization approaches such as self-built + partnership and supply chain + franchise models, we enhance the competitiveness of our clinic business.
More
New Service Solutions
Jointown has been strengthening service awareness: manufacturer services involve providing medical insurance and centralized procurement qualification support to secure distribution rights; digital intelligence services encompass SPD, medical consortium systems, smart traditional Chinese medicine pharmacy systems, Zhiyaotong, Mendiantong, traceability, flow analysis, and more; C-end services include insurance, personal health management, single-disease management, B2C, and others; along with comprehensive health-related collaborative services.
More
Digital Intelligence
Built on a foundation of big data, AI, Internet of Things, and other technologies, Jointown empowers business competitiveness, improves management and operational efficiency, enhances digital decision-making capabilities, and builds an intelligent supply chain system, advancing from digitalization toward digital intelligence.
More
Capitalization
Through market capitalization management, REITs, spin-off IPOs, mergers and acquisitions, equity investments and other means, Jointown provides financial support for strategic expansion and innovation, optimize the balance sheet, enhance market valuation, and achieve long-term sustainable value creation.
More

Group Leadership

More
Board Of Directors
Management Team

Development History

2024 2025
Credit Quality Upgrade August 25, the company's main credit rating was upgraded to AAA with a stable rating outlook, making it the only private enterprise in the pharmaceutical distribution industry to obtain the AAA credit rating.

Corporate Honors

More
No. 165 - Fortune China 500 (2025) Fortune
No. 55 - Top 500 Chinese Private Enterprises 2024 All-China Federation of Industry & Commerce
2024 Information Disclosure Rating "A" Shanghai Stock Exchange
2024 ESG Advancement Contribution Award China Association of Pharmaceutical Commerce
2024 Top 100 Listed Companies for SME Investor Protection CG50 Forum (5th Theme Forum of the 18th China Corporate Governance Forum)
Special Contribution Award of the Year 2024 Red Cross Society of China Hubei Branch